SEC Form 4 · accession 0000882104-15-000071
PDL BIOPHARMA, INC. · PDLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steffen Pietzke
Officer — Controller and CAO
Period of report
Sep 29, 2015
Accepted (ET)
Oct 5, 2015 · 6:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882104
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Sep 29, 2015 | A | 1,841 | $4.95 | A | 16,589 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved, based upon the following schedule: 50% on December 2016; 16.66% on December 2017; 16.66% on December 2018; and 16.66% on December 2019.